In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.

You may also be interested in...

Stentys SAS

The design of currently marketed stents is not optimal in treating stenosis in or next to coronary bifurcations. Stentys, founded by noted cardiologist and entrepreneur Jacques Séguin, MD, PhD, aims to improve on outcomes while keeping things simple. It believes its bifurcation stent will be as easy for cardiologists to use as conventional stents, but that its novel design will provide superior clinical results by enabling full opening and scaffolding of the side branch.

Relypsa Inc.

When Amgen bought Ilypsa last summer, it kept one of its non-absorbed polymer drug candidates for itself, leaving Ilypsa's other candidates in limbo. Key Ilypsa employees and investors wanted to carry out those programs, and with Amgen's blessing, they moved swiftly to form Relypsa Inc., which retains rights to Ilypsa's remaining pipeline and drug discovery platform. Relypsa management, all from Ilypsa, intends to continue Ilypsa's fast pace of pipeline development, with a NCE planned for entry into the clinic every year for the next three years.

Thrombotargets Corp.

Company executives at Thrombotargets hit the ground running upon its 2005 founding in Barcelona, Spain. In two years, they have developed a pipeline of 11 hemostatics, anticoagulants, antiplatelets and fibrinolytics, all enabled by the company's proprietary high-throughput screening process, BioPlatformScreen. Thrombotargets is now preparing for clinical trials of its lead candidate, an antihemorrhagic human recombinant protein that has received FDA orphan drug status for two indications.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts